Clinical

Dataset Information

0

38-502:BRAFTOVI/MEKTOVI Combination Therapy Specified Drug Use Survey(CRC)


ABSTRACT: Primary outcome(s): [Safety]Occurrence status of adverse drug reactions and infections, Occurrence status of adverse drug reactions corresponding to specified safety concerns, Factors that are considered to affect safety Specified safety concerns: Cutaneous malignancies, palmar-plantar erythrodysaesthesia syndrome, eye disorders, cardiac dysfunction, hypertension, rhabdomyolysis, hepatic dysfunction, and haemorrhage [Efficacy]Antitumor effect and overall survival (OS)

DISEASE(S): Unresectable Advanced Or Recurrent Braf-mutant Colorectal Cancer

PROVIDER: 2613085 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2613087 | ecrin-mdr-crc
2019-02-01 | GSE121421 | GEO
| PRJNA550004 | ENA
2024-09-18 | GSE275871 | GEO
| PRJNA1070820 | ENA
2024-04-15 | GSE250341 | GEO
2013-07-31 | E-GEOD-47068 | biostudies-arrayexpress
2010-06-24 | GSE21335 | GEO
2013-07-31 | GSE47068 | GEO
2015-08-27 | E-GEOD-65405 | biostudies-arrayexpress